BridgeBio Pharma Inc. (NASDAQ: BBIO) reported Q2 EPS of ($0.95), $0.20 worse than the analyst estimate of ($0.75). Revenue for the quarter came in at $110.56 million versus the consensus estimate of $99.72 million.

For earnings history and earnings-related data on BridgeBio Pharma Inc. (BBIO) click here.